Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to investigate the feasibility of a possible treatment regimen that could be used to delay tumor progression in patients with glioblastoma. The study is being conducted in patients who qualify for inpatient rehabilitation, as this population is particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in the period between surgical resection and the start of treatment.

Clinical Trial Description

This is a pilot study to evaluate the feasibility and safety of early postsurgical temozolomide therapy prior to initiation of standard chemoradiation regimen in patients with glioblastoma who undergo inpatient rehabilitation. The study will be conducted with adult patients who qualify for inpatient rehabilitation following surgical resection of pathologically confirmed Grade IV glioma. Patients will begin a 21-day cycle of temozolomide starting 14 days after surgery at 75mg per square meter of body surface area daily to serve as bridge therapy. Patients will then progress to receive standard therapy following their rehabilitation stay. Patients will be assessed for their ability to complete the chemotherapy protocol without dose-limiting toxicity as well as complete inpatient rehabilitation successfully. Additionally, we will be assessing for tumor progression between the time of surgery and the time of treatment initiation. If this study shows the expected results, the research team plans to proceed to a larger trial assessing the efficacy of early TMZ in patients with glioblastoma (GBM) who are admitted to acute inpatient rehabilitation compared to the current standard of care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03796507
Study type	Interventional
Source	University of Rochester
Contact
Status	Withdrawn
Phase	Early Phase 1
Start date	September 1, 2021
Completion date	December 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04406610` - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Active, not recruiting	`NCT03189420` - Glioma Microenvironment an Exploratory Study
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Active, not recruiting	`NCT03739372` - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma	N/A
Completed	`NCT03779230` - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse	Phase 1/Phase 2
Recruiting	`NCT03728673` - A Study Utilizing Escitalopram in Glioma Patients	Phase 2
Active, not recruiting	`NCT03496181` - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting	`NCT03180697` - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas	N/A
Recruiting	`NCT03949192` - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Terminated	`NCT03927274` - Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma	Early Phase 1
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Not yet recruiting	`NCT03763396` - Azoles Targeting Recurrent High Grade Gliomas	Early Phase 1
Terminated	`NCT03698201` - Blood Biomarker Signature in Glioma
Terminated	`NCT03436433` - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis	Phase 2
Recruiting	`NCT03750890` - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation	`NCT03102112` - Noninvasively Predicting Gene Status of Glioma	N/A
Active, not recruiting	`NCT03935685` - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ	Phase 2
Completed	`NCT03834740` - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Early Phase 1
Recruiting	`NCT03849430` - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients